Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review
VaccinesRespiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Fangrui Ding
exaly +5 more sources
Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network [PDF]
Human Vaccines & ImmunotherapeuticsAlthough clinical trials have shown that nirsevimab is safe, post-licensure safety data from routine clinical settings are lacking. This study describes parent-reported health events occurring within seven days of nirsevimab administration.
Marina Viñeta Paramo +11 more
doaj +2 more sources
Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study [PDF]
Pediatric Pulmonology, Volume 61, Issue 6, June 2026.ABSTRACT Introduction New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.
Adria Rose +4 more
wiley +2 more sources
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants [PDF]
Pediatric Pulmonology, Volume 61, Issue 6, June 2026.ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Marine Tarizzo +7 more
wiley +2 more sources
Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center [PDF]
Molecular and Cellular PediatricsBackground Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data
Moritz Bauer +4 more
doaj +2 more sources
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
New England Journal of Medicine, 2023 The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear.In a pragmatic trial, we randomly assigned, in a 1:1 ratio, infants who were 12 months of age or younger, had been born at a
Pierre Tissières +2 more
exaly +6 more sources
Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States [PDF]
VaccinesBackground/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal ...
Klodeta Kura +7 more
doaj +2 more sources
Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study [PDF]
Infectious Diseases and TherapyIntroduction Germany’s Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect ...
Caroline Lade +8 more
doaj +2 more sources
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study [PDF]
Infectious Diseases and TherapyIntroduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff +10 more
doaj +2 more sources
PathogensBackground: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV
Amanda Leach +2 more
exaly +3 more sources